Market capitalization | $125.52b |
Enterprise Value | $118.40b |
P/E (TTM) P/E ratio | 30.16 |
EV/FCF (TTM) EV/FCF | 35.57 |
EV/Sales (TTM) EV/Sales | 8.78 |
P/S ratio (TTM) P/S ratio | 9.31 |
P/B ratio (TTM) P/B ratio | 4.45 |
Revenue growth (TTM) Revenue growth | 6.46% |
Revenue (TTM) Revenue | $13.49b |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
28 Analysts have issued a Regeneron Pharmaceuticals forecast:
28 Analysts have issued a Regeneron Pharmaceuticals forecast:
Jun '24 | |
Current assets | 19,082 19,082 |
Fixed assets | 17,005 17,005 |
Total Assets | 36,087 36,087 |
Jun '24 | |
Equity | 28,206 28,206 |
Debt capital | 7,881 7,881 |
Total Capital | 36,087 36,087 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Head office | United States |
CEO | Leonard Schleifer |
Employees | 13,450 |
Founded | 1988 |
Website | www.regeneron.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.